Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 707 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Nudge Intervention
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational Accepts healthy volunteers

BRINK (BRain In Kidney Disease) Memory Study 2.0

NCT04975464
Conditions
Chronic Kidney Diseases, Dementia, Dementia, Vascular, Stroke, Alzheimer Disease, Cognitive Decline, Cognitive Impairment, Cognitive Dysfunction, Kidney Diseases, Diabetes, Cerebral Atrophy, Small Vessel Ischemic Disease
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
1,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
64
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 61 more
Conditions
Agitation in Participants With Dementia of the Alzheimer's Type
Interventions
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
Conditions
Alzheimer Disease
Interventions
Vielight Neuro Gamma, Sham Vielight Neuro Gamma
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
San Francisco, California
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Frontotemporal Lobar Degeneration, Memory Disorders
Interventions
Nautilus NeuroWaveTM System
Device
Lead sponsor
Jan Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Type2 Diabetes
Interventions
Tailored Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Conditions
Alzheimer Disease
Interventions
Self-Guided Lifestyle Intervention, Structured Lifestyle Intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 79 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
6
States / cities
Sacramento, California • Chicago, Illinois • Downers Grove, Illinois + 3 more
Conditions
Frailty, Cognitive Impairment, Dementia, Cognitive Impairment, Mild, Alzheimer Disease, Alzheimer Disease, Early Onset
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
50 Years to 95 Years
Enrollment
100 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Mild Cognitive Impairment
Interventions
Mindfulness Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed No phase listed Observational Accepts healthy volunteers

Biomarkers and Early Alzheimer's Disease

NCT00094952
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Mild Cognitive Impairment
Interventions
NewGam 10% IVIG, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Sacramento, California
Completed No phase listed Observational Accepts healthy volunteers

Brain Health & the Microbiome

NCT06039267
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer Disease 1
Interventions
Gut Microbiome Testing
Other
Lead sponsor
George Washington University
Other
Eligibility
50 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Alzheimer Disease
Interventions
Placebo, BI 409306, Donepezil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Sherman Oaks, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

NCT01044758
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
ABT-957, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Cypress, California • Orlando, Florida • The Villages, Florida + 6 more
Conditions
Alzheimer's Disease
Interventions
MK-1942, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more
Conditions
Mild Cognitive Impairment
Interventions
mnemonic strategy training, spaced retrieval training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Alzheimer Disease, Dementia Alzheimers, Dementia, Cognitive Impairment, Mild Cognitive Impairment, Neurodegenerative Diseases, Neurocognitive Disorders, Neurocognitive Dysfunction, Cognitive Dysfunction, Mental Disorder
Interventions
Emerald Device Monitoring
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Not listed
Lead sponsor
NeuroVision Imaging
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Conditions
Postoperative Delirium, Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Interventions
Dextrose Water, Caffeine citrate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
70 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Alzheimer Disease
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more
Not listed No phase listed Observational Accepts healthy volunteers

The A-LIST WMM Insights Series

NCT04466722
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
UsAgainstAlzheimer's
Other
Eligibility
18 Years to 100 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more